<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823211</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-KVO-2</org_study_id>
    <secondary_id>Plasek680-2</secondary_id>
    <nct_id>NCT01823211</nct_id>
  </id_info>
  <brief_title>Profitability Trial in Primary Preventive Implantable Cardioverter-defibrillator Recipients</brief_title>
  <acronym>HAPPIER</acronym>
  <official_title>Heart Rate Variability, Microvolt T-wave Alternans and Cardiac Magnetic Resonance Imaging Analysis in Primary Preventive ImplantablE Cardioverter-defibrillator Recipients Profitability Trial - HAPPIER Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is further risk stratification of patients receiving implantable
      cardioverter-defibrillator in primary prevention of sudden cardiac death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current criteria for risk stratification of patients in risk of sudden cardiac death are
      mainly based on left ventricular ejection fraction and NYHA class. This criteria are too
      robust, approximately 2/3 of ICD recipients do not profit from this treatment in the
      following 5 years, especially those with non-ischaemic cardiomyopathy. We plan to
      sub-stratify this group of patients with both ischaemic and non-ischaemic cardiomyopathy by:
      non-linear heart rate variability analysis, microvolt T-wave alternans, QRT-T angle and
      character and amount of left ventricular scarring assessed by magnetic resonance imaging.
      Pre-implantation values will be correlated with numbers and character of ICD therapy (both
      anti-tachycardial pacing and ICD discharge). The results may allow to decrease the number of
      patients, who do not profit from ICD treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with ensuring patient examinations defined in the protocol of the study
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>ventricular tachyarrhytmia</measure>
    <time_frame>36 months</time_frame>
    <description>ventricular tachycardia equal or &gt; 250/min,ventricular fibrillation, arrhythmic storm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sudden cardiac death</measure>
    <time_frame>36-months</time_frame>
    <description>death in 24-hours after symptom onset</description>
  </secondary_outcome>
  <other_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>36-months</time_frame>
    <description>mortality from both cardiovascular and non-cardiovascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>36-months</time_frame>
    <description>death from strictly cardiovascular cause</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Ischaemic Cardiomyopathy</condition>
  <condition>Non-ischaemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ischaemic cardiomyopathy</arm_group_label>
    <description>EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ischaemic cardiomyopathy</arm_group_label>
    <description>EP study,magnetic resonance imaging with LGE, ICD implantation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Heart-failure clinic,primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVD (left ventricular dysfunction) d/t MI (Myocardial infarction), LVEF 30% or less,
             NYHA (New York Heart association class) II, III

          -  LVD d/t MI, LVEF 30% to 35%, NYHA II, III

          -  LVD d/t MI, LVEF 30% to 40%, NSVT, positive EP study

          -  LVD d/t MI, LVEF 30% or less, NYHA I

          -  NICM (non-ischaemic cardiomyopathy), LVEF 30% or less, NYHA II, III

          -  NICM, LVEF 30% to 35%, NYHA II, III

          -  NICM, LVEF 30% or less, NYHA I

          -  signed informed consent

        Exclusion Criteria:

          -  metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in
             their brain, cannot have an MRI scan since the magnetic field may dislodge the metal

          -  severe claustrophobia may not be able to tolerate an MRI scan

          -  heart rhythm device in place before enrollment

          -  atrial fibrillation in time of enrollment

          -  ICD implantation indicated from secondary prevention of SCD (sudden cardiac death)

          -  NYHA or CCS class IV

          -  PCI or CABG in last 3 months

          -  CMP/TIA in last 3 months

          -  syncope of unknown etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiri Plasek, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology,University hospital Ostrava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milos Taborsky, MD, PhD, FESC</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology,University Hospital Olomouc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lubos Krivan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology,University Hospital Brno-Bohunice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ondrej Moravec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology,University Hospital Olomouc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brno University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Seely AJ, Macklem PT. Complex systems and the technology of variability analysis. Crit Care. 2004 Dec;8(6):R367-84. Epub 2004 Sep 22. Review.</citation>
    <PMID>15566580</PMID>
  </reference>
  <reference>
    <citation>Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006 Sep;8(9):746-837. Epub 2006 Aug 25.</citation>
    <PMID>16935866</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICD (Implantable cardioverter-defibrillator)</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>MTWA (Microvolt T-alternans)</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

